BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 20452227)

  • 1. Analogs of zanamivir with modified C4-substituents as the inhibitors against the group-1 neuraminidases of influenza viruses.
    Wen WH; Wang SY; Tsai KC; Cheng YS; Yang AS; Fang JM; Wong CH
    Bioorg Med Chem; 2010 Jun; 18(11):4074-84. PubMed ID: 20452227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of acylguanidine zanamivir derivatives as neuraminidase inhibitors and the evaluation of their bio-activities.
    Lin CH; Chang TC; Das A; Fang MY; Hung HC; Hsu KC; Yang JM; von Itzstein M; Mong KK; Hsu TA; Lin CC
    Org Biomol Chem; 2013 Jun; 11(24):3943-8. PubMed ID: 23695381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based design and synthesis of C-1- and C-4-modified analogs of zanamivir as neuraminidase inhibitors.
    Feng E; Shin WJ; Zhu X; Li J; Ye D; Wang J; Zheng M; Zuo JP; No KT; Liu X; Zhu W; Tang W; Seong BL; Jiang H; Liu H
    J Med Chem; 2013 Feb; 56(3):671-84. PubMed ID: 23330908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase.
    Varghese JN; Epa VC; Colman PM
    Protein Sci; 1995 Jun; 4(6):1081-7. PubMed ID: 7549872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs?
    Cheng CK; Tsai CH; Shie JJ; Fang JM
    Future Med Chem; 2014 May; 6(7):757-74. PubMed ID: 24941871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities.
    Ye D; Shin WJ; Li N; Tang W; Feng E; Li J; He PL; Zuo JP; Kim H; Nam KY; Zhu W; Seong BL; No KT; Jiang H; Liu H
    Eur J Med Chem; 2012 Aug; 54():764-70. PubMed ID: 22795831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuraminidase inhibitor drug susceptibility differs between influenza N1 and N2 neuraminidase following mutagenesis of two conserved residues.
    Ho HT; Hurt AC; Mosse J; Barr I
    Antiviral Res; 2007 Dec; 76(3):263-6. PubMed ID: 17868928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A practical synthesis of zanamivir phosphonate congeners with potent anti-influenza activity.
    Shie JJ; Fang JM; Lai PT; Wen WH; Wang SY; Cheng YS; Tsai KC; Yang AS; Wong CH
    J Am Chem Soc; 2011 Nov; 133(44):17959-65. PubMed ID: 21942552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three new powerful oseltamivir derivatives for inhibiting the neuraminidase of influenza virus.
    Wang SQ; Cheng XC; Dong WL; Wang RL; Chou KC
    Biochem Biophys Res Commun; 2010 Oct; 401(2):188-91. PubMed ID: 20849817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effect of zanamivir-porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus.
    Wen WH; Lin M; Su CY; Wang SY; Cheng YS; Fang JM; Wong CH
    J Med Chem; 2009 Aug; 52(15):4903-10. PubMed ID: 19522501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism-based covalent neuraminidase inhibitors with broad-spectrum influenza antiviral activity.
    Kim JH; Resende R; Wennekes T; Chen HM; Bance N; Buchini S; Watts AG; Pilling P; Streltsov VA; Petric M; Liggins R; Barrett S; McKimm-Breschkin JL; Niikura M; Withers SG
    Science; 2013 Apr; 340(6128):71-5. PubMed ID: 23429702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
    Kawai N; Ikematsu H; Hirotsu N; Maeda T; Kawashima T; Tanaka O; Yamauchi S; Kawamura K; Matsuura S; Nishimura M; Iwaki N; Kashiwagi S
    Clin Infect Dis; 2009 Dec; 49(12):1828-35. PubMed ID: 19911968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.
    Smith PW; Sollis SL; Howes PD; Cherry PC; Starkey ID; Cobley KN; Weston H; Scicinski J; Merritt A; Whittington A; Wyatt P; Taylor N; Green D; Bethell R; Madar S; Fenton RJ; Morley PJ; Pateman T; Beresford A
    J Med Chem; 1998 Mar; 41(6):787-97. PubMed ID: 9526555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase.
    Watson KG; Cameron R; Fenton RJ; Gower D; Hamilton S; Jin B; Krippner GY; Luttick A; McConnell D; MacDonald SJ; Mason AM; Nguyen V; Tucker SP; Wu WY
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1589-92. PubMed ID: 15006410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of 1,2,3-triazole-containing N-acyl zanamivir analogs as potent neuraminidase inhibitors.
    Das A; Adak AK; Ponnapalli K; Lin CH; Hsu KC; Yang JM; Hsu TA; Lin CC
    Eur J Med Chem; 2016 Nov; 123():397-406. PubMed ID: 27487569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus.
    Wang SQ; Du QS; Huang RB; Zhang DW; Chou KC
    Biochem Biophys Res Commun; 2009 Aug; 386(3):432-6. PubMed ID: 19523442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
    Ferraris O; Kessler N; Lina B
    Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of human H1N1 influenza virus variants selected in vitro with zanamivir in the presence of sialic acid-containing molecules.
    Giannecchini S; Campitelli L; Bandini G; Donatelli I; Azzi A
    Virus Res; 2007 Nov; 129(2):241-5. PubMed ID: 17765996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuraminidase inhibitor R-125489--a promising drug for treating influenza virus: steered molecular dynamics approach.
    Mai BK; Li MS
    Biochem Biophys Res Commun; 2011 Jul; 410(3):688-91. PubMed ID: 21693105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of replication of avian influenza viruses by the neuraminidase inhibitor 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid.
    Gubareva LV; Penn CR; Webster RG
    Virology; 1995 Oct; 212(2):323-30. PubMed ID: 7571401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.